<DOC>
	<DOCNO>NCT02076529</DOCNO>
	<brief_summary>This study designted know optimal dose Ramosteron control chemotherapy induce nasea vomoting ( CINV ) base pharmacokinetics , pharmacodynamic study clinilcal parameter use Rhodes Index .</brief_summary>
	<brief_title>Phamacokinetic Pharmacodynamic Study Ramosetron Chemotherapy Induced Nasea Vomiting</brief_title>
	<detailed_description>Nausea vomit common adverse event chemotherapy treatment . Even preventive medicine dopamine receptor antagonist , corticosteroid , serotonin receptor antagonist , develop use , residual nausea and/or vomit significant percentage patient treat cancer . Serotonin receptor antagonist potent antiemetic agent use widely . However , optimal dose serotonin antagnosit base individual symptom define . Therefore , study conduct design standardization model optiomal serotonin antagonist concentration use pharmacodynamic study Rhodes Index suggogate marker CINV .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>Patients recevied moderate emetogenic chemotherapy Age 1875 ECOG PS 02 Adequate organ fuction include bone marrow , liver kidney Gastrointestinal obstruction carcinomatosis peritonei CNS metastasis disability CNS Intractable medical illness Pregnancy inadequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>chemotherapy induce nausea vomiting</keyword>
</DOC>